Lewy Body Dementia

Lewy body dementia, or LBD, is a chronic, progressive neurodegenerative disorder and represents the second most common form of dementia. LBD is characterized by a build-up of abnormal proteins known as Lewy bodies in areas of the brain that control cognition, movement, alertness, and behavior.

Lewy body dementia includes two similar conditions – dementia with Lewy bodies, or DLB, and Parkinson’s disease dementia, or PDD. The primary difference between both conditions generally depends on the timing of the onset of cognitive decline relative to the onset of movement-related symptoms.

In dementia with Lewy bodies, cognitive decline generally occurs within one year of the onset of movement disorder symptoms. In Parkinson’s disease dementia, movement disorder symptoms precede cognitive decline by more than a year.

Along with suffering from impaired cognition and behavioral disturbances, LBD patients often suffer from:

R

Visual hallucinations

R

Fluctuations in cognition, attention, and alertness

R

Sensitivity to neuroleptic (antipsychotic) medications

R

REM behavior disorder, or RBD, in which people physically act out their dreams

R

Parkinsonism (movement disorder symptoms such as muscle rigidity, tremors)

The Lewy Body Dementia Association estimates there are 1.4 million patients with Lewy body dementia in the United States.

Axovant is currently developing two drug candidates to treat certain aspects of Lewy body dementia – intepirdine (RVT-101) and nelotanserin. Currently, there are no drugs approved by FDA for the treatment of DLB. Intepirdine has the potential to be the first drug approved by the FDA for the treatment of DLB.